Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Afatinib Formulations in Healthy Males
NCT02171715Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2009
- Primary completion
- Apr 2009
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of afatinib in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity up to 96 hours and Maximum measured concentration of the analyte in plasma up to 96 hours. Started Jan 2009; status: completed.
02
Drugs
afatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02171715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02171715.